TP53 and cancer: This typically includes near-ubiquitous mutations in key tumor suppressor genes, namely, TP53 and RB1, both of which contribute substantially to the aggressive behavior of the cancer and represent major obstacles in the development of effective targeted therapeutic strategies [4,6].